A Hospice DME Per Diem Is Only as Good as Its Formulary

When hospice organizations evaluate DME vendors, the conversation often begins and ends with the per diem rate. A lower number appears to signal better value and stronger cost control.

But per diem rates alone tell only part of the story.

The true financial outcome of a hospice DME contract is driven by the formulary behind the rate. What is included. What is excluded. How exceptions are priced when utilization deviates from assumptions.

A per diem is only as good as what it actually covers.

Two vendors may offer nearly identical per diem rates and still deliver very different all in costs per patient day. The difference lies in the structure of their formularies.

Comparing per diems without comparing formularies introduces financial risk. One vendor may include commonly used items while excluding higher acuity equipment. Another may bundle certain items but impose strict utilization caps or premium pricing once thresholds are exceeded. On paper, the per diems appear comparable. In practice, the economics are not.

Non formulary items are where cost variability accelerates. Once utilization extends beyond what is bundled, pricing becomes highly sensitive to patient mix, length of stay, and vendor specific rate structures. A model that appears inexpensive at signing can become costly once real world utilization is applied.

This is where many finance teams experience surprise. Not because utilization is inappropriate, but because the pricing model assumed a level of predictability that hospice care rarely delivers.

In response, some hospices gravitate toward more expansive formularies. The logic is straightforward. Include more items. Reduce exceptions. Limit surprise charges.

But expansive formularies carry their own tradeoffs.

Paying a higher per diem to cover equipment that is rarely used means prepaying for risk that may never materialize. Every patient day absorbs that cost regardless of actual utilization. Over time, baseline spend increases without delivering proportional value.

By contrast, a more targeted formulary paired with disciplined utilization management can produce a lower all in cost per patient day. This approach allows hospices to pay for high cost items only when clinically necessary, rather than embedding that risk into every per diem by default.

The difference is structural.

Formularies become financial outcomes through utilization behavior, clinical practice patterns, and operational workflows. Without visibility into how real world utilization interacts with the formulary, per diem comparisons can be misleading and financially dangerous.